CDX2 and head and neck squamous cell carcinoma: Taken together, our research elucidates the molecular mechanism how the CDX2/CXCL14 axis enhances NK cell–mediated immunotherapy against HNSCC, in which CDX2 stimulates the cytotoxicity of NK cells through up‐regulation of CXCL14 (Figure 7).